Anti-PCSK9 Monotherapy for Hypercholesterolemia

Michael J. Koren; Pernille Lundqvist; Michael A. Bolognese; Joel M. Neutel; Maria Laura Monsalvo; Jingyuan Yang; Jae B. Kim; Robert C. Scott; Scott M. Wasserman; Harold Bays

doi:10.1016/j.jacc.2014.03.018

Keywords

EvolocumabPlaceboEzetimibeMedicinePCSK9Internal medicineGastroenterologyAlirocumabAdverse effectUrologyPharmacologyEndocrinologyCholesterolLipoproteinPathologyLDL receptor

Affiliated Institutions

Related Publications

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H. Jones , Michael H. Davidson , Evan A. Stein +5 more

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...

2003 The American Journal of Cardiology 1382 citations

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Erin A. Bohula , Robert P. Giugliano , Christopher P. Cannon +6 more

Background— Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C an...

2015 Circulation 327 citations

Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease

Jonathan C. Cohen , Eric Boerwinkle , Thomas H. Mosley +1 more

These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even ...

2006 New England Journal of Medicine 3106 citations

Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])

Harold Bays , Carlos A. Dujovne , Mark E. McGovern +4 more

This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...

2003 The American Journal of Cardiology 153 citations

Publication Info

Year: 2014
Type: article
Volume: 63
Issue: 23
Pages: 2531-2540
Citations: 395
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Anti-PCSK9 Monotherapy for Hypercholesterolemia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

395

OpenAlex

Cite This

APA Style

                            
                                
                                    Michael J. Koren, 
                                
                                    Pernille Lundqvist, 
                                
                                    Michael A. Bolognese
                                
                                et al.
                            
                            (2014). 
                            Anti-PCSK9 Monotherapy for Hypercholesterolemia. 
                            Journal of the American College of Cardiology
                            , 63
                            (23)
                            , 2531-2540.
                            https://doi.org/10.1016/j.jacc.2014.03.018
                        

Identifiers

DOI: 10.1016/j.jacc.2014.03.018